AUTHOR=Zhu Wanwan , Zhao Tianhao , Wei Jun , Chai Damin , Zhao Cancan , Zhu Yu , Deng Min TITLE=Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis JOURNAL=Frontiers in Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.942237 DOI=10.3389/fmed.2022.942237 ISSN=2296-858X ABSTRACT=

Extraintestinal manifestations are common in patients with inflammatory bowel disease, while respiratory involvement is less common. Vedolizumab is a new class of anti-integrin biological agents approved for treating inflammatory bowel disease. In this report, we present the case of a 38-year-old patient with ulcerative colitis for 7 years who developed cough, fever, and pulmonary infiltrates after taking vedolizumab. There was a spontaneous improvement in clinical symptoms and radiological abnormalities after discontinuing vedolizumab and introducing steroids. Despite the rarity of vedolizumab-induced eosinophilic pneumonia, the case reports indicate that patients with unexplained respiratory symptoms that are taking vedolizumab should be fully contemplated.